Disease · EFO_1001283

Candidiasis, Invasive

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Candidiasis, Invasive. Diseases, record EFO_1001283. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001283

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Candidiasis, Invasive; Open Targets
Open Targets ID: EFO_1001283; Open Targets
MeSH: D058365; MeSH
Highest stage of its drugs: Approval, for 2 of its 13 drugs, from EMA Human Drugs and FDA; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
REZAFUNGIN	CHEMBL3989945	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
REZAFUNGIN ACETATE	CHEMBL3989928	Small molecule	Approval	FDA	1	0	0	Drugs and targets
MICAFUNGIN	CHEMBL457547	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
ANIDULAFUNGIN	CHEMBL264241	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CASPOFUNGIN	CHEMBL1630575	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
FLUCONAZOLE	CHEMBL106	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CASPOFUNGIN ACETATE	CHEMBL5314378	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
FOSMANOGEPIX	CHEMBL4297591	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
VORICONAZOLE	CHEMBL638	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00413218	Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections	Phase 3	450	2017-08-01	Candidiasis, Invasive, Candidemia, Mycoses	CASPOFUNGIN, ISAVUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00689338	Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study	Phase 3	216	2011-05-17	Invasive Candidiasis	ANIDULAFUNGIN, FLUCONAZOLE, VORICONAZOLE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02734862	CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension	Phase 2	207	2020-12-08	Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis	CASPOFUNGIN, FLUCONAZOLE, REZAFUNGIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00250432	A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)	Phase 3	204	2009-03-24	Invasive Candidiasis	CASPOFUNGIN ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03667690	Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis	Phase 3	199	2023-01-06	Candidemia, Mycoses, Fungal Infection, Invasive Candidiases	CASPOFUNGIN, FLUCONAZOLE, REZAFUNGIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00717860	A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)	Phase 3	121	2011-08-26	Fungal Infection	CASPOFUNGIN, MICAFUNGIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00761267	Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis	Phase 3	70	2018-09-14	Candidemia	ANIDULAFUNGIN, FLUCONAZOLE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00672841	β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients	Not applicable	64	2013-04-22	Invasive Candidiasis	ANIDULAFUNGIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00635648	A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)	Phase 3	63	2012-05-28	Fungal Infection	CASPOFUNGIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01945281	Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)	Phase 2	51	2018-08-28	Candidiasis, Invasive	AMPHOTERICIN B, CASPOFUNGIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials22

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Isavuconazole (ISA) vs Caspofungin (CAS)/Voriconazole: deaths from any cause	55 of 220	55 of 220	440	NCT00413218	Trial comparisons
Isavuconazole (ISA) vs Caspofungin (CAS)/Voriconazole: serious adverse events	112 of 220	106 of 220	440	NCT00413218	Trial comparisons
Caspofungin 70/50 mg vs Caspofungin 150 mg: Number of Patients Who Develop Significant Drug-related Adverse Events.	2 of 104	3 of 100	204	NCT00250432	Trial comparisons
Caspofungin 70/50 mg vs Caspofungin 150 mg: Number of Patients With a Favorable Overall Response.	73 of 102	74 of 95	197	NCT00250432	Trial comparisons
Group 1: Rezafungin for Injection vs Group 2: Caspofungin: deaths from any cause	29 of 98	25 of 98	196	NCT03667690	Trial comparisons
Group 1: Rezafungin for Injection vs Group 2: Caspofungin: serious adverse events	55 of 98	52 of 98	196	NCT03667690	Trial comparisons
Caspofungin vs Micafungin: Number of Participants With a Significant Drug-related Adverse Experience	3 of 60	6 of 60	120	NCT00717860	Trial comparisons
Caspofungin vs Micafungin: serious adverse events	12 of 60	14 of 60	120	NCT00717860	Trial comparisons
Active Surveillance, Preemptive Therapy vs Standard Care, Empiric Treatment: serious adverse events	0 of 47	0 of 17	64	NCT00672841	Trial comparisons
Active Surveillance, Preemptive Therapy vs Standard Care, Empiric Treatment: Incidence of Proven or Probable Invasive Fungal Infection (IFI)	3 of 41	3 of 17	58	NCT00672841	Trial comparisons

1 to 10 of 22

See all 22 comparisons in its trials

Papers from its trials35

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37596890	RESULT	1	PubMed
37022196	RESULT	1	PubMed
34374424	RESULT	1	PubMed
31586424	RESULT	1	PubMed
23052987	RESULT	1	PubMed
41940006	DERIVED	2	PubMed
41194465	DERIVED	1	PubMed
39529079	DERIVED	2	PubMed
39468640	DERIVED	2	PubMed
39259571	DERIVED	1	PubMed

1 to 10 of 35

See all 35 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001283

GET https://conductscience.org/api/diseases/v1/EFO_1001283/trials?page=2

API reference For AI assistants